Loading organizations...
Mint12 Pharma is a venture capital firm specializing in strategic investments across biotechnology and pharmaceuticals. The firm focuses on funding companies developing new, patented core technologies. Through capital deployment, Mint12 Pharma aims to accelerate transformative healthcare solutions, building a robust portfolio of innovative ventures.
Founded in 2022, Mint12 Pharma was established by managing partner David Adams. Drawing from over thirty years in investment management, Adams recognized the critical need for focused capital and guidance for early-stage life science breakthroughs. This expertise underpins the firm’s ability to support promising therapeutic advancements effectively.
The firm's stakeholders are innovative biotech and pharmaceutical startups seeking growth capital and strategic partnership. Mint12 Pharma envisions itself as a pivotal partner in bringing groundbreaking medical technologies to market. Its mission centers on fostering the next generation of life-changing scientific discoveries through selective investment and active portfolio management.
Mint12 Pharma has 1 tracked investment across 1 company. The latest tracked deal is $3.0M Seed in Myosin Therapeutics in March 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 3, 2025 | Myosin Therapeutics | $3.0M Seed | Dave Adams, DeepWork Capital, Florida Opportunity Fund, Mint12 Pharma | Dynagrow Capital, Mayo Clinic, Sontag Foundation |
